Latest Conference

The chief scientific officer and medical director of Segal Trials shares more on KarXT, a first in class for muscarinic agonists, and what he's excited about at the upcoming 2024 APA Annual Meeting.

Our Editorial Board members are delivering expert perspectives on a wide variety of psychiatric issues and disorders.

How can psychiatric clinicians improve outcomes for this unique patient population?

How can novel technologies help address stigma and improve care for patients with SUDs?

What are the cultural psychiatry perspectives on personality disorders? Don't miss this APA session!

Are you coming to the 2024 APA Annual Meeting? We'll see you there!

Let us know if we'll see you there!

Here’s why you should attend the Yale Child Study Center Black Youth Mental Health Case Conference.

Psychiatric Times highlighted takeaways from the 2023 American College of Neuropsychopharmacology Annual Meeting in our February issue. Don't miss out on these important conference clinical pearls!

Learn more about the inaugural Black Youth Mental Health Clinical Case Conference Series at Yale Child Study Center, a 6-session event in 2024, that focuses on improving mental health care for Black youth and their families.

Check out these APSARD 2024 updates from Greg Mattingly, MD, president of the American Professional Society for ADHD and Related Disorders.

This APSARD 2024 conference poster finds that individuals with ADHD have distinct motivations and patterns of substance use.

The results were shared in a poster presentation at the 2024 APSARD Annual Meeting.

Ann Childress, MD, the current president of APSARD, invites you to attend this year's conference!

In an exclusive interview, APSARD President Elect Greg Mattingly, MD, tells Psychiatric Times readers what they can expect at this year's meeting.

Did you miss the 2023 Annual Psychiatric Times World CME Conference? Don't worry, we've got you covered.

Updates from Day 2 at the National Academy of Sciences Conference on adult ADHD.

Check out these updates for the National Academy of Sciences Conference on adult ADHD, including new research, thoughtful discussions, and more!

These important findings on esketamine nasal spray as a treatment for young individuals with suicidal ideation were presented at the ACNP 2023 Annual Meeting. We interviewed the vice president and head of neuropsychiatry clinical development at Johnson & Johnson Innovative Medicine to learn more.

What neuromodulation can be used to specifically target nicotine users with schizophrenia? This research may tell us.

ECT: a gold-standard treatment for major depressive disorder. Ketamine/esketamine: a newer therapeutic option. This ACNP 2023 Annual Meeting session took a deeper look.

This ACNP 2023 Annual Meeting poster covered a 26-week study on cariprazine as an adjunctive treatment to antidepressants in patients with major depressive disorder.

Deep brain stimulation for substance use disorders when everything else fails, the history of the ACNP, and more.

Research presented at the ACNP 2023 Annual Meeting shows that neuromodulation therapy cTBS could be a viable schizophrenia-specific intervention for nicotine use.

Exciting research ideas are stirring at the ACNP 2023 Annual Meeting.

Neurosteroid therapeutics could be the solution to provide fast-acting treatment for mothers with postpartum depression.

Check out these brief summaries on cognitive impairment in schizophrenia from an excellent session at the ACNP 2023 Annual Meeting!

DBS in psychiatry: What challenges stand between this treatment and success? Alik Widge, MD, PhD, shares more at the ACNP 2023 Annual meeting.

Did you catch the President's Plenary at the ACNP 2023 Annual Meeting?

Navacaprant—a novel, oral, once-daily, highly selective kappa opioid receptor antagonist that is currently in phase 3 development as a monotherapy for major depressive disorder.